STOCK TITAN

Navidea Biopharmaceuticals, Inc. - $NAVB STOCK NEWS

Welcome to our dedicated page for Navidea Biopharmaceuticals news (Ticker: $NAVB), a resource for investors and traders seeking the latest updates and insights on Navidea Biopharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Navidea Biopharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Navidea Biopharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
-
Rhea-AI Summary
Navidea Biopharmaceuticals provides details on its financial results for Q1 2023 and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
-
Rhea-AI Summary
Navidea Biopharmaceuticals, Inc. received a Notice from the NYSE American stating that it is not in compliance with the continued listing standards. The Company has until December 1, 2023, to demonstrate sustained price improvement or effect a reverse stock split. The Notice has no immediate effect on the listing or trading of the Company's common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Navidea Biopharmaceuticals, Inc. introduces Fix, Fund, Propel approach to drive strategic objectives. The company will issue a press release for Q1 2023 results instead of a conference call and webcast. G2G Ventures is supporting the company's strategic planning and change initiatives. The Fix component focuses on strong leadership, clear priorities, and well-defined roles. Fund aims to secure non-dilutive funding options and partnerships for short, medium, and long-term liquidity. Propel involves creating or improving revenue growth in targeted markets. The company will file Form 10-Q for Q1 2023 and issue a press release with first quarter highlights on May 12th, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.54%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.75%
Tags
management
Navidea Biopharmaceuticals, Inc.

AMEX:NAVB

NAVB Rankings

NAVB Stock Data

4.00M
64.07M
35.89%
0.01%
2.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Dublin

About NAVB

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de